Alpha-1 Antitrypsin Deficiency: Clinical Manifestations
Alpha-1 antitrypsin deficiency primarily manifests as basilar, pan-lobular emphysema leading to COPD, with liver disease (cirrhosis) as the second major presentation, and less commonly causes bronchiectasis, necrotizing panniculitis, and ANCA-positive vasculitis 1.
Pulmonary Manifestations
The respiratory system is the most commonly affected organ system:
- COPD with emphysema - The classic presentation features basilar, pan-lobular emphysema with airflow obstruction (FEV1/FVC <0.7), which differs from the typical apical distribution seen in smoking-related COPD 1
- Adult-onset asthma with persistent airflow obstruction - Patients develop asthma in adulthood that progresses to fixed airway obstruction 1
- Unexplained bronchiectasis - Bronchiectasis without clear etiology should prompt testing 1, 2
Critical pitfall: Symptoms typically appear earlier and progress more rapidly in smokers. The combination of genetic deficiency plus smoking exposure dramatically accelerates lung destruction 1.
Hepatic Manifestations
- Liver cirrhosis - Results from accumulation of misfolded Z-variant AAT protein in hepatocytes, causing progressive liver damage 3, 4
- Can present across the lifespan, from neonatal hepatitis to adult cirrhosis 3
Other Clinical Manifestations
Less common but important presentations include:
- Necrotizing panniculitis - Painful subcutaneous nodules, typically on trunk and extremities 1, 4, 2
- ANCA-positive vasculitis (granulomatosis with polyangiitis) - Systemic vasculitis associated with severe deficiency 1, 2
Asymptomatic Presentation
A critical caveat: Many individuals with severe deficiency remain asymptomatic throughout life, representing a spectrum from no symptoms to progressively debilitating disease 2. This wide variability makes targeted testing essential rather than waiting for symptoms to develop.
Key Clinical Context
The most severe deficiency occurs with the Pi*ZZ genotype, resulting in AAT levels <11 μmol/L (<57.2 mg/dL or <0.57 g/L), which confers markedly increased risk for both pulmonary and hepatic complications 1, 5, 4. The disease remains substantially underdiagnosed, with only an estimated 5-10% of cases identified 4, 6, meaning most affected individuals never receive appropriate counseling or disease-specific management.
Environmental factors, particularly smoking, dramatically modify disease expression - smoking cessation is therefore the single most important intervention regardless of genotype 1.